16 : 14 Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC et al
Takeaway: Semaglutide 7.2 mg doesnt surpass tirzepatide, but it meaningfully closes the gapoffering another escalation path in obesity care
But the findings still raise more red flags about the potential risks of GLP-1 medications
This lack of absolute specificity raises concerns about off-target effects, particularly given the potential for unintended gene activation in noncardiac tissues
Additionally, the serum levels of total IgE, IL4, and IL5 were significantly lower in the naringenin group, indicating a decrease in allergic inflammation
A healthcare provider can help determine whether oral or injectable weight loss are the right options based on your health profile